
Asthma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051136

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines the PBS subsidised biological agents for patients
with severe asthma.

Asthma and listing dates

Asthma is a common long-term inflammatory disease of the airways of the
lungs.

Different biological agents require different blood results in order to
treat different types of severe asthma.

Listings dates:

-   omalizumab - 1 July 2011
-   mepolizumab - 1 January 2017
-   benralizumab - 1 December 2018
-   dupilumab - 1 April 2021

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item codes, restriction, the Pharmaceutical Benefits Scheme (PBS), the
Services Australia websites and the ACQ-5 assessment form.

Related links

Written Authority Required Drugs

Processing Written Authority Required Listings

Process telephone Authority approval application

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing and National Demand Allocation (PaNDA)

                                   

-   Services Australia ABN 90 794 605 008 
